drugset
drugset / Trial / NCT05143281

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

NCT05143281 ↗

Phase 4 Completed 23 enrolled Grene Vision Group Ocular Therapeutix, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.

Timeline

Start
2021-12-13
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other

Indications

cataract